Takeda, Zinfandel link may revive ACTOS in Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Takeda became the latest of the major pharmaceutical companies to turn to biomarker-based diagnostics its approach to Alzheimer’s disease when it signed an exclusive, worldwide licensing agreement with Zinfandel Pharmaceuticals on the development of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease. However, recently published research elsewhere suggests that a full understanding of the biology of the disease may not be necessary in identifying potential Alzheimer's diagnostics.